Rakuten on April 17
Jiangsu Hengrui Pharmaceutical Co., Ltd. (stock code: 600276, stock abbreviation: Hengrui Pharmaceutical) today released its financial results for the first quarter of 2024. According to the financial report, Hengrui Pharmaceutical's revenue in the first quarter of 2024 will be 5.998 billion yuan, a year-on-year increase of 9.2%.
Hengrui Pharmaceutical's government subsidy included in the first quarter of 2024 is 40.32 million yuan.
During the reporting period, the company received a down payment of €160 million from Merck Healthcare, and the relevant performance obligations have not yet been completed, and the relevant revenue has not yet been recognized.
Hengrui Pharmaceutical's net profit in the first quarter of 2024 was 1.369 billion yuan, a year-on-year increase of 10.48%, and the net profit after deducting non-profits was 1.44 billion yuan, a year-on-year increase of 18.06%.
Hong Kong Securities Clearing Company Limited increased its holdings
As of March 31, 2024, Jiangsu Hengrui Pharmaceutical Group Co., Ltd. held 24.11% of the shares, Tibet Dayuan Enterprise Management Co., Ltd. held 14.94% of the shares, and Hong Kong Securities Clearing Co., Ltd. held 6.09% of the shares;
As of March 31, 2024, Hengrui Pharmaceutical's shareholding structure
China National Pharmaceutical Investment Co., Ltd. holds 3.78% of the shares, Qingdao Bosentai Investment Partnership (Limited Partnership) holds 2.86% of the shares, Lianyungang Financial Holding Group Co., Ltd. holds 1.84% of the shares, China Securities Finance Co., Ltd. holds 1.5% of the shares, and Industrial and Commercial Bank of China Co., Ltd. - China-Europe Medical and Health Hybrid Securities Investment Fund holds 1.3% of the shares.
The Industrial and Commercial Bank of China-SSE 50 ETF holds 1.17% of the shares, and the China Construction Bank Corporation-E Fund CSI 300 Medical and Health ETF holds 1.01%.
As of December 31, 2023, Jiangsu Hengrui Pharmaceutical Group Co., Ltd. held 24.11% of the shares, Tibet Dayuan Enterprise Management Co., Ltd. held 14.94% of the shares, and Hong Kong Securities Clearing Co., Ltd. held 5.08% of the shares;
As of December 31, 2023, Hengrui Pharmaceutical's shareholding structure
China National Pharmaceutical Investment Co., Ltd. holds 3.78% of the shares, Qingdao Bosentai Investment Partnership (Limited Partnership) holds 2.86% of the shares, Lianyungang Financial Holding Group Co., Ltd. holds 1.83% of the shares, China Securities Finance Co., Ltd. holds 1.5% of the shares, and Industrial and Commercial Bank of China Co., Ltd. - Sino-Europe Medical and Health Hybrid Securities Investment Fund holds 1.37% of the shares;
China Construction Bank Corporation-E Fund CSI 300 Pharmaceutical and Health Exchange-traded Open-ended Index Securities Investment Fund holds 1.05% of the shares, and Central Huijin Asset Management Co., Ltd. holds 0.91% of the shares.
The comparison shows that Hong Kong Securities Clearing Co., Ltd. increased its holdings in the first quarter of 2024.
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.